Compounded Ozempic and Wegovy, cheaper generic versions of the weight-loss drugs, can no longer be sold. Doctor explains options for patients on the drugs.
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has asked the FDA to approve it.
The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic (semaglutide) and to refrain from using the imitation drugs.
As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking off. But do these products work?
Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as well as its injected blockbuster Ozempic. The stock dropped as much as 9.8% to 380 kroner early in Copenhagen, the first trading day since the Thursday announcement that buoyed Lilly. The triumph … Read more
Abstract Aims Glucagon-like peptide-1 (GLP-1) receptor agonists, alongside dual receptor agonists targeting glucose-dependent insulinotropic polypeptide (GIP) receptors, represent transformative therapies for obesity management. Despite their increasing use, patient perspectives of these treatments remain underexplored. This exploratory study aimed to examine the experiences and attitudes of individuals using GLP-1 medications (GLP-1s) for weight loss, focusing on … Read more
A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of glucose-lowering drugs used in type 2 diabetes, were associated with a significantly reduced risk of Alzheimer’s disease and related dementias (ADRD). These findings suggest potential neuroprotective benefits and highlight drug repurposing as a promising strategy for ADRD prevention.
GLP-1 medications like Ozempic may help reduce alcohol cravings and support recovery—especially when combined with therapy and used to treat coexisting conditions.
HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced publication of the results of a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya’s investigational biologic combination to suppress pro-inflammatory myeloid cells, enhance … Read more
Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.